MedTrace Logo

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

NCT06799611 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-03-13

No results posted yet for this study

Summary

To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia

Conditions

  • Immune Thrombocytopenia (ITP)
  • Treatment

Interventions

DRUG

CM336 Injection

subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Lei Zhang, MD · Chinese Academy of Medical Science and Blood Disease Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2026-01-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06799611 on ClinicalTrials.gov